News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
323,653 Results
Type
Article (19326)
Company Profile (126)
Press Release (304201)
Section
Business (104925)
Career Advice (856)
Deals (18473)
Drug Delivery (83)
Drug Development (50471)
Employer Resources (79)
FDA (7565)
Job Trends (7707)
News (184891)
Policy (17261)
Tag
Academia (725)
Africa (406)
Alliances (27599)
Alzheimer's disease (517)
Antibody-drug conjugate (ADC) (38)
Approvals (7536)
Arizona (43)
Artificial intelligence (50)
Asia (24208)
Australia (3110)
Bankruptcy (170)
Best Places to Work (5334)
Biosimilars (56)
Biotechnology (59)
C2C Services and Suppliers (13097)
California (766)
Canada (510)
Cancer (192)
Cardiovascular disease (30)
Career advice (693)
Cell therapy (36)
China (72)
Clinical research (40955)
Collaboration (68)
COVID-19 (1046)
Cystic fibrosis (41)
Data (103)
Diabetes (45)
Diagnostics (1659)
Drug pricing (74)
Earnings (37682)
Employer resources (71)
Europe (49792)
Events (46728)
Executive appointments (74)
FDA (7650)
Florida (97)
Funding (45)
Gene therapy (53)
GLP-1 (416)
Government (1768)
Healthcare (5820)
Hotbed/Location (218918)
Illinois (88)
Indiana (72)
Infectious disease (1062)
Inflammatory bowel disease (56)
Interviews (113)
IPO (7238)
IRA (31)
Job creations (2424)
Job search strategy (642)
Kansas (53)
Layoffs (240)
Legal (4057)
Lung cancer (47)
Manufacturing (60)
Maryland (122)
Massachusetts (667)
Medical device (1927)
Medtech (1928)
Mergers & acquisitions (11141)
Metabolic disorders (198)
Minnesota (58)
Neuroscience (597)
New Jersey (309)
New York (231)
NextGen Class of 2024 (2339)
Non-profit (897)
North Carolina (282)
Northern California (356)
Obesity (130)
Ohio (46)
Opinion (164)
Patents (51)
Pennsylvania (226)
People (32570)
Pharmaceutical (62)
Phase I (12711)
Phase II (17357)
Phase III (13984)
Pipeline (66)
Podcasts (47)
Policy (50)
Postmarket research (1607)
Preclinical (4466)
Rare diseases (77)
Real estate (3160)
Regulatory (11905)
Research institute (814)
Resumes & cover letters (138)
South America (600)
Southern California (319)
Startups (2003)
Texas (86)
The Weekly (31)
United States (3426)
Vaccines (163)
Washington State (93)
Weight loss (131)
Date
Last 7 days (287)
Last 30 days (1002)
Last 365 days (18631)
2024 (12542)
2023 (19647)
2022 (25881)
2021 (26643)
2020 (24872)
2019 (20058)
2018 (15588)
2017 (17255)
2016 (16202)
2015 (18801)
2014 (14788)
2013 (12552)
2012 (13482)
2011 (13817)
2010 (12738)
323,653 Results for "vifor pharma".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Policy
CSL Vifor Offers Marketing Campaign to Reverse Alleged Anti-Competitive Practices
Following an investigation regarding antitrust practices against Pharmacosmos’ Monofer, CSL Vifor has proposed a sweeping multi-channel communication campaign designed to reverse allegedly misleading messages about its rival.
April 22, 2024
·
2 min read
·
Tristan Manalac
Policy
CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
CSL Vifor and Travere Therapeutics, Inc., announced that the European Commission has granted conditional marketing authorization for FILSPARI for the treatment of adults with primary IgAN with a urine protein excretion ≥1.0 g/day.
April 24, 2024
·
7 min read
Policy
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
Travere Therapeutics, Inc., and CSL Vifor announced that the European Commission has granted conditional marketing authorization for FILSPARI for the treatment of adults with primary IgA nephropathy with a urine protein excretion ≥1.0 g/day.
April 24, 2024
·
16 min read
Biotech Beach
CSL Vifor and Travere Therapeutics announce sparsentan receives positive CHMP opinion for the treatment of IgA nephropathy
CSL Vifor and Travere Therapeutics, Inc., announced that the European Medicines Agency’s CHMP has recommended approval of sparsentan for the treatment of adults with primary IgAN with a urine protein excretion >1.0 g/day. IgAN is a rare kidney disorder and a leading cause of kidney failure.
February 23, 2024
·
5 min read
Drug Pricing
Akebia Ends Deal With CSL Vifor, Unveils Hefty Price Tag for CKD Anemia Drug Vafseo
Akebia Therapeutics on Thursday said it regained full U.S. rights to its chronic kidney disease anemia drug Vafseo, which the biotech has priced at around $15,500 per year.
July 12, 2024
·
2 min read
·
Tristan Manalac
Policy
Approval of delisting of Vifor Pharma AG’s registered shares
Vifor Pharma AG announced that Vifor has received approval for the delisting of the totality of Vifor’s registered shares.
October 12, 2022
·
3 min read
Business
Astellas Pharma Opens Cambridge Life Sciences Center Featuring Incubator Space
Astellas Pharma’s new life sciences center houses its first U.S.-based SakuLab, an incubator space for external partners, as well as its engineered small molecules unit.
September 6, 2024
·
1 min read
·
Angela Gabriel
Cancellation of remaining publicly held registered shares of Vifor Pharma AG
Vifor Pharma AG announced that the Commercial Court St. Gallen has cancelled all remaining publicly held registered shares of Vifor with a nominal value of CHF 0.01 each.
December 14, 2022
·
3 min read
Policy
EU Nephrologists Foresee Travere/CSL Vifor’s FILSPARITM (sparsentan) Transforming IgA Nephropathy Treatment as the First Non-Immunosuppressive Therapy
Over the past several years, glomerular diseases have garnered significant attention from the nephrology industry, largely driven by the persistent unmet needs present for patients grappling with these rare conditions.
April 30, 2024
·
5 min read
Mergers & acquisitions
Broken Deals: 4 Pharma Assets Returned to Biotech This Year
Not all licensing deals are successful. Here,
BioSpace
examines a few noteworthy assets that Big Pharma returned in the last 12 months.
August 27, 2024
·
5 min read
·
Mollie Barnes
1 of 32,366
Next
